When we think about next-gen therapies that eliminate disease-causing proteins, most attention goes to the “targeting” components—the parts that bind to harmful proteins or cellular cleanup crews. But there’s a quiet powerhouseRead More…
Drug discovery is experiencing an unobtrusive revolution. Researchers have advanced past just blocking dangerous proteins and now pursue methods to actively break them down which could enable treatments for previously untreatable diseases. The foundationRead More…
Introduction Targeted Protein Degradation (TPD) has become a revolutionary way to work for the treatment of many diseases, yet they have been very successful in the treatment of diseases that have beenRead More…
In the relentless pursuit of modern medicine, Targeted Protein Degradation (TPD) has emerged as a revolutionary therapeutic strategy, offering new hope for the treatment of numerous diseases. Traditional small-molecule inhibitors mainly actRead More…
Introduction Proteolysis-targeting chimeras (PROTEIN-TARGETING CHIMERASs) are a new class of small molecules that provide alternative ways to discover drugs by leading target proteins to be selectively destroyed. In contrast to conventional inhibitors thatRead More…
Chen, Po-Han, et al. “Modulation of phosphoprotein activity by phosphorylation targeting chimeras (PhosTACs).” ACS chemical biology 16.12 (2021): 2808-2815. In the rapidly evolving field of drug development, targeting protein post-translational modifications (PTMs) has emergedRead More…
Protein targeted degradation chimera is an emerging protein degradation strategy that has been booming in recent years. It was first proposed by Craig Crews et al. in 2001. Its basic principle isRead More…
Nef is an accessory protein encoded by HIV-1, HIV-2, and other primate lentiviruses and is closely related to viral replication, persistent infection, and the development of AIDS. Nef interacts with a varietyRead More…
The field of drug discovery is witnessing a revolutionary shift with the advent of Proteolysis Targeting Chimeras (PROTACs). This innovative therapeutic strategy is redefining how we approach the degradation of proteins, especiallyRead More…
Proteolysis targeting chimera (PROTAC) technology represents a breakthrough development in the field of drug discovery, utilizing the ubiquitin proteasome system to specifically degrade disease-related proteins. PROTACs are characterized by their unique heterobifunctionalRead More…